J-147

J147 is a synthetic small molecule, a curcumin derivative designed at the Salk Institute and now owned by Abrexa Pharmaceuticals. It is not a peptide. A completed Phase 1 trial established safety and pharmacokinetics in humans, and a Phase 2 acute-stroke trial is currently recruiting, making J147 unusually far along in human development compared with most compounds this site covers, but no completed human trial has yet tested whether it actually works, for stroke, Alzheimer’s disease, or any other indication.

Ask about J147

Research snapshot

Peptide categoryNot a peptide: synthetic small molecule, curcumin derivative
Primary research interestAcute ischemic stroke neuroprotection (current Phase 2 focus); originally developed for Alzheimer’s disease
Highest available evidenceCompleted human Phase 1 safety/pharmacokinetics trial; Phase 2 acute-stroke efficacy trial recruiting
Human research availableYes, for safety/PK; no completed human efficacy trial for any indication
Development statusPhase 2 (JUMPSTART, acute ischemic stroke, recruiting)
Regulatory statusInvestigational; not approved for human use anywhere

Technical identity

Primary nameJ147
Alternative namesJ 147; CAD-31 precursor compound; J147 curcumin derivative
Peptide sequenceNot applicable: this is a small molecule, not a peptide
Amino-acid lengthNot applicable
Molecular formulaNot independently re-verified in this pass; consult a chemical database directly
Molecular weightNot independently re-verified in this pass
CAS Registry NumberNot independently re-verified in this pass
PubChem CIDNot independently re-verified in this pass
UNIINot reliably established
DrugBank IDNot listed
Chemical modificationsNot applicable in the peptide sense, a curcumin-derivative small molecule
Peptide classNot a peptide: curcumin-derivative small molecule
Primary biological targetMitochondrial ATP synthase (reported inhibition), with downstream effects on cellular NAD+ and acetyl-CoA levels
Developer or originatorDavid Schubert and Pamela Maher’s laboratory, Salk Institute; now owned by Abrexa Pharmaceuticals, Inc.
Development statusPhase 2 (acute ischemic stroke)

What it is

J147 is a synthetic small molecule, a curcumin derivative, designed by David Schubert and Pamela Maher’s laboratory at the Salk Institute using a phenotypic screening approach in aged mice rather than starting from a single known drug target. It is not a peptide. It is now owned by Abrexa Pharmaceuticals, Inc., which is running its human clinical development program.

Proposed mechanisms described in the reviewed literature include inhibition of mitochondrial ATP synthase and downstream effects on cellular NAD+ and acetyl-CoA levels, changes linked in mouse studies to reduced markers of brain aging; separately, J147 has been reported in mouse studies to stimulate markers of neurogenesis and improve dendritic structure.

Potential benefits and research applications

Neuroprotection in acute ischemic stroke, the indication now in human Phase 2 testing

J147’s proposed mitochondrial and neurogenic mechanisms are now being tested clinically in acute ischemic stroke patients undergoing endovascular clot removal, in the JUMPSTART Phase 2 trial. This is a safety-and-dose-finding study with imaging and clinical outcomes as secondary endpoints, and it has not reported results.

Evidence: is being investigated in an ongoing human Phase 2 trial (Tier 2, registered but unpublished human trial); has not been established as effective, since the trial has not reported results.

Alzheimer’s disease and broader neuroprotection, supported only by mouse and cell-culture data so far

J147 was originally identified and developed around proposed benefits in Alzheimer’s disease, based on mouse studies showing reduced markers of brain aging, increased neurogenesis markers, and improved dendritic structure, linked to inhibition of mitochondrial ATP synthase and changes in cellular NAD+ and acetyl-CoA levels.

Evidence: has been shown in mouse and cell-culture studies (Tier 3-4, published animal and laboratory evidence); has not been established in any human trial for Alzheimer’s disease specifically, and no such trial is currently registered.

Depression, diabetic neuropathy and fatty liver disease, preliminary mouse findings not yet in human testing

Additional mouse studies have reported benefits for J147 in models of depression, diabetic neuropathy and fatty liver disease, extending its proposed mechanism beyond neuroprotection alone.

Evidence: has been reported in mouse studies (Tier 3, published animal evidence); is being investigated only insofar as the compound’s general safety profile is now established in humans, not these specific indications.

Where its human development actually stands

A completed Phase 1 trial (Abrexa Pharmaceuticals, NCT03838185) gave single ascending oral doses of J147 to 64 healthy young and elderly volunteers in a randomized, double-blind, placebo-controlled design, to assess safety, tolerability and pharmacokinetics. Specific dose levels tested were not disclosed in the public trial record reviewed for this entry. This was a safety and PK study; it was not designed or powered to show any benefit.

As of this entry’s last check, a Phase 2 trial (NCT07430917, “JUMPSTART”) is recruiting, testing a single intravenous bolus of a J147 injectable formulation, given alongside mechanical thrombectomy, in patients with acute ischemic stroke undergoing endovascular clot removal. This is a safety-and-dose-finding study with imaging and clinical outcome measures as secondary endpoints; it has not reported results.

No completed human efficacy trial for J147, in stroke, Alzheimer’s disease, or any other indication, was located for this entry. Everything published about a benefit in Alzheimer’s disease, depression, diabetic neuropathy or fatty liver disease is a mouse or cell-culture finding.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. The only completed human trial for J147 measured safety and pharmacokinetics, not benefit, and did not publicly disclose specific dose levels.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Phase 1 safety and pharmacokinetics (healthy young and elderly volunteers)OralSingle ascending doses; specific mg levels not disclosed in the public trial record reviewedSingle dose per cohortNot specifiedRegistered, completed human trial (NCT03838185)
Phase 2, acute ischemic stroke (JUMPSTART, alongside endovascular thrombectomy)Intravenous bolusNot yet disclosed (dose-finding)Single IV bolusTrial ongoing, recruiting since July 2026Registered, ongoing human trial (NCT07430917)
Cognitive/neuroprotective support, general (research-chemical/community use)OralVaries by listingVaries by listingVaries by listingCommunity/vendor reported: no published effective human dose exists to check against

What is not known

Whether J147 does anything beneficial in a human being. The only completed human trial measured safety and pharmacokinetics, not efficacy, and the efficacy trial now underway has not reported results.

What dose, if any, will be carried forward from the ongoing Phase 2 stroke trial, and whether an effective human dose exists at all.

Whether any of the mouse findings in Alzheimer’s disease, depression or other indications will be tested in a dedicated human trial for those indications specifically, rather than the acute stroke population now being studied.

Frequently asked questions

What is J147?

J147 is a synthetic small molecule, a curcumin derivative designed at the Salk Institute using a phenotypic screening approach in aged mice. It is not a peptide, and it is now owned by Abrexa Pharmaceuticals.

How does J147 work?

Proposed mechanisms include inhibition of mitochondrial ATP synthase, changes in cellular NAD+ and acetyl-CoA levels, and stimulation of neurogenesis markers, all established so far in mouse and cell-culture studies.

What dosage has been studied in humans?

A completed Phase 1 trial gave single ascending oral doses to 64 healthy young and elderly volunteers, but specific dose levels were not disclosed in the public trial record reviewed for this entry.

What dosage commonly circulates online?

Research-chemical listings describe oral capsule or powder use at doses that vary by seller. No published effective human dose exists to check that figure against, since the only completed human trial measured safety and pharmacokinetics, not benefit.

Has J147 been studied in humans?

Yes. A Phase 1 safety and pharmacokinetics trial is complete, and a Phase 2 acute-stroke trial (JUMPSTART) is currently recruiting. No completed human efficacy trial exists yet.

Is J147 approved for use?

No. It is investigational and not approved for human use anywhere.

What routes of administration are reported?

The Phase 1 trial used oral dosing; the ongoing Phase 2 stroke trial uses an intravenous bolus formulation.

Does J147 treat Alzheimer’s disease?

This has not been established. The Alzheimer’s-related findings are entirely from mouse and cell-culture studies; no dedicated human Alzheimer’s trial for J147 is currently registered.

What side effects have been reported?

The completed Phase 1 trial assessed safety and tolerability, but specific results were not detailed in the public record reviewed for this entry.

What remains unknown about J147?

Whether it does anything beneficial in a human being, since the only completed trial measured safety, not efficacy; what dose the ongoing stroke trial will settle on; and whether its mouse findings in other indications will ever reach dedicated human trials.

Bottom line

J147 stands out for having a real, dated, active human clinical development program, a completed Phase 1 safety trial and a recruiting Phase 2 stroke trial, further along than most compounds this site covers. But “further along” does not mean proven: the only completed human trial measured safety and pharmacokinetics, not whether the drug actually works, and every benefit claim for Alzheimer’s disease, depression, diabetic neuropathy or fatty liver disease remains a mouse or cell-culture finding awaiting its own dedicated human trial.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Cognitive/neuroprotective support, generalOralVaries by listingVaries by listingVaries by listing

Circulating research-chemical listings for J147 describe oral capsule or powder use at doses that vary by seller. The completed human trial for this compound tested single ascending oral doses in a controlled clinical setting without publicly disclosing the dose levels used, and it measured safety and blood levels, not any beneficial effect. There is no published effective human dose for any purpose to check a circulating figure against.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Live registry status

These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.

TrialPhaseStatusSponsorEnrolledPrimary completionRegistry updated
Safety and Efficacy of J147 in Acute Ischemic Stroke
NCT07430917
Phase 2RecruitingAbrexa Pharmaceuticals, Inc.196Mar 1, 2028Aug 24, 2026
Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147
NCT03838185
Phase 1CompletedAbrexa Pharmaceuticals, Inc.64Feb 1, 2020Sep 3, 2020

Open these in the trial tracker

Research area: Neuro and cognitive.

Share thisFacebookXEmail